|
Funding Agency: National Institutes of Health Title: Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional) Application Deadline: November 22, 2023 This initiative will solicit research to target gaps in knowledge about barriers and facilitators to ring use, interventions to improve uptake, adherence, and persistence on the vaginal ring, and implementation science studies to improve access to and distribution of the ring. Research topics may include, but are not limited to: studies of individual, interpersonal, and structural factors that are barriers and facilitators to uptake of, adherence to, and persistence on the vaginal ring when the ring is delivered in real world settings (i.e., outside of clinical or open label extension trials); development and testing of behavioral interventions to encourage uptake, consistent use of, and persistence on the vaginal ring; and implementation science studies to understand implementation barriers and facilitators to delivery of the vaginal ring, and to optimize delivery of the ring. Funding Agency: National Institutes of Health Title: The National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) Small Business Innovation Research (SBIR) Program Application Deadline: November 14, 2023 The purposes of the SBIR program are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. Funding Agency: National Institutes of Health Title: Developing Salivary Components as Therapeutics for Oral Health (R01 Clinical Trial Not Allowed) Application Deadline: November 22, 2023 This FOA will encourage interdisciplinary research that harnesses the functional components of saliva towards therapeutics. It is expected that outcomes will facilitate development of highly effective surrogate saliva for clinical applications. Funding Agency: National Institutes of Health Title: Initiative to Maximize Research Education in Genomics: Diversity Action Plan (R25 Clinical Trials Not Allowed) Application Deadline: November 15, 2023; January 25, 2024; January 27, 2025 The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: (1) Courses for Skills Development; and (2) Research Experiences. This notice of funding opportunity (NOFO) seeks to expose undergraduate and post-baccalaureate level students to the foundational sciences relevant to genomics to enable them to pursue careers that span all areas of interest to NHGRI - genome sciences, genomic medicine, genomics and society, genomic data science, and genomics and health equity. For the purposes of this NOFO, the term “genomics” encompasses issues and activities in these five areas. Funding Agency: National Institutes of Health Title: Biotypes of CNS Complications in People Living with HIV (P01 Clinical Trial Not Allowed) Application Deadline: December 11, 2023 HIV associated CNS complications are a significant problem for people living with HIV despite suppressive anti-retroviral therapy. HIV enters the CNS as early as 8 days after infection and can cause several complications including cognitive, neurological and mental health related issues. Although experts have gathered much data on underlying HIV-induced CNS pathophysiology, specific targeted causality remains elusive, and no effective therapies exist to slow, stop, or reverse these adverse outcomes. This initiative is to comprehend the actionable biotypes of CNS complications in people living with HIV based on underlying mechanisms to help capture the heterogeneity of outcomes. Identifying biotypes can inform the development of precision treatment strategies for CNS complications seen in people living with HIV. Funding Agency: National Institutes of Health Title: Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed) Application Deadline: January 31, 2024 This Notice of Funding Opportunity announcement (NOFO) supports systematic and scalable approaches to profile the biological function of genes with an excess of damaging mutations in patients with neurodevelopmental and psychiatric disorders. Current understanding of the relationship between genetic and phenotypic variation is limited and one of the main bottlenecks in translating disease-associated genes to biology lies in the lack of scalable experimental platforms that can extend the unbiased nature of gene discovery to the discovery of biological mechanisms. Funding Agency: National Institutes of Health Title: Research Tools for Difficult to Culture Eukaryotic Pathogens (R61/R33 Clinical Trial Not Allowed) Application Deadline: February 02, 2024 The purpose of this Notice of Funding Opportunity (NOFO) is to support high risk, milestone-driven approaches for the development of robust culture techniques, and/or genetic and molecular tools to better understand the biology of select human eukaryotic pathogens including the microsporidian Enterocytozoon bieneusi; Pneumocystis jirovecii; Plasmodium vivax; and Babesia microti. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase will depend on the successful completion of milestones. Funding Agency: National Institutes of Health Title: Diagnostic Centers of Excellence for the Undiagnosed Diseases Network (U01 Clinical Trial Not Allowed) Application Deadline: November 03, 2023 The purpose of this Notice of Funding Opportunity is to solicit applications for clinical sites that will provide expert diagnostic services for undiagnosed diseases across the nation. The clinical sites known as Diagnostic Centers of Excellence (DCoEs) will partner with the Undiagnosed Diseases Network (UDN) to sustain some of the key research activities currently performed by the Phase II UDN Clinical sites (see:RFA-RM-17-019) and facilitate its transition to a larger network that serves diverse undiagnosed patient populations. The DCoEs will establish collaborations and efficient processes with the Data Management and Coordinating Center (DMCC; see: RFA-NS-22-051); enroll and evaluate new participants; and foster scientific discovery. Funding Agency: Centers for Disease Control and Prevention Title: Research Grants for Preventing Violence and Violence Related Injury (R01) Application Deadline: December 01, 2023 The Centers for Disease Control and Prevention's National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research that will help expand and advance understanding of approaches to prevent community violence and eliminate racial and ethnic inequities in risk for community violence. This initiative is intended to support effectiveness research to evaluate innovative programs, practices, or policies to address risk for violence and inequities in risk for violence among groups experiencing a high burden of community violence. Innovative approaches are those that have not been rigorously evaluated for effectiveness in reducing community violence. Funding Agency: Centers for Disease Control and Prevention Title: Research Grants to Identify Effective Community-Based Strategies for Overdose Prevention (R01) Application Deadline: December 01, 2023 The Centers for Disease Control and Prevention’s (CDC) National Center for Injury Prevention and Control (NCIPC, Injury Center) is soliciting investigator-initiated research to partner with communities to develop and rigorously evaluate the effectiveness of new, innovative, under-developed, or untested community-based strategies/interventions/programs/practices to reduce overdose. Funding Agency: National Institutes of Health Title: Firearm Injury Prevention in Community Healthcare Settings (R01 Clinical Trial Optional) Anticipated Application Deadline: November 07, 2023 The purpose of this notice is to inform the research community that the National Institute of Nursing Research (NINR) intends to promote a new initiative by publishing a Request for Applications (RFA) to advance research that reduces firearm injury and disparities through the development and evaluation of firearm injury primary prevention interventions leveraging community healthcare settings. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This RFA will utilize the R01 activity code. Details of the planned RFA are provided below. Funding Agency: National Institutes of Health Title: Short Courses in Social Determinants of Health for Research Education in Nursing Research (R25 Independent Clinical Trial Not Allowed) Anticipated Application Deadline: December 15, 2023 The National Institute of Nursing Research (NINR) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to establish a Short Course in Social Determinants of Health (SDOH) to provide research education in nursing research. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in early fall 2023 with an expected application due date in early winter 2023. This NOFO will utilize the Research Education Program (R25) activity code with a focus on Courses for Skills Development. Details of the planned NOFO are provided below. Funding Agency: National Institutes of Health Title: Information and Practice Needs Relevant to Late Talking Children (R21 Clinical Trial Not Allowed) Anticipated Application Deadline: February 01, 2024 The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. Late talking, also known as late language emergence, is diagnosed when a child, usually over the age of 18 months, is not meeting expressive language milestones. Approximately 10% to 20% of children receive this diagnosis. Children may be at higher risk for late talking for a variety of reasons including, but not limited to, premature birth, exposure to maltreatment or trauma, and intellectual and developmental disorders; and yet other children present as late talkers for no other known reason and with no other symptoms. Funding Agency: National Institutes of Health Title: Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed) Anticipated Application Deadline: February 01, 2024 The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. Late talking, also known as late language emergence, is diagnosed when a child, usually over the age of 18 months, is not meeting expressive language milestones. Approximately 10% to 20% of children receive this diagnosis. Children may be at higher risk for late talking for a variety of reasons including, but not limited to, premature birth, exposure to maltreatment or trauma, and intellectual and developmental disorders; and yet other children present as late talkers for no other known reason and with no other symptoms. Funding Agency: National Institutes of Health Title: Nursing Research Education Program in Firearm Injury Prevention Research: Short Courses (R25 Independent Clinical Trial Not Allowed) Anticipated Application Deadline: December 15, 2023 The National Institute of Nursing Research (NINR) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to establish a Short Course in Firearms Injury Prevention to provide research education in nursing research. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in early fall 2023 with an expected application due date in early winter 2023/2024. This NOFO will utilize the R25 activity code. Details of the planned NOFO are provided below. Funding Agency: National Institutes of Health Title: High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional) Anticipated Application Deadline: November01, 2023 This Notice informs the research community that the National Institute on Aging (NIA) intends to issue a Request for Applications (RFA) for new and renewal applications to provide critical network support for advancing development in the following specific high-priority areas of behavioral and social research on aging: (1) Stress Measurement, (2) Life Course Health Disparities at Older Ages, (3) Aging Research on Criminal Justice and Health Disparities, (4) Rural Aging, (5) Genomics of Behavioral and Social Science, (6) Behavioral and Social Research on Aging in Animal Models. Funding Agency: National Institutes of Health Title: BRAIN Initiative Connectivity across Scales Data Coordinating Center (BRAIN CONNECTS DCC) (U24 Clinical Trial Not Allowed) Anticipated Application Deadline: December 15, 2023 The Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative intends to issue a Notice of Funding Opportunity (NOFO) to solicit applications for one or more Data Coordinating Centers (DCCs) to support BRAIN CONNECTS, a networked consortium of Comprehensive Centers and Specialized Projects funded under RFA-NS-22-047, RFA-NS-22-048, and RFA-NS-22-049. The goals of BRAIN CONNECTS awards are to develop the research capacity and technical capabilities for comprehensive brain-wide connectivity mapping in mouse, human, and non-human primate (NHP). BRAIN CONNECTS projects will collect and process unprecedented volumes of anatomical data by scaling up cutting-edge acquisition modalities and analysis methods, to demonstrate the feasibility and potential impact of production, analysis, dissemination, and interpretation of connectivity maps from entire brains. The resulting feasibility data from these awards are expected to inform NIH decisions on program continuation in a potential subsequent five-year funding period for production of brain-wide wiring diagrams. Funding Agency: National Institutes of Health Title: NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) Anticipated Application Deadline: February 16, 2024 The planned R34 notice of funding opportunity (NOFO) intends to support studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, the planned NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders.
|
